Evaxion and Pantherna announce promising preclinical mRNA vaccine data
February 08 2023 - 6:30AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage biotechnology company specializing in the
development of AI-powered immunotherapies and Pantherna
Therapeutics GmbH (“Pantherna”), a biopharmaceutical company
developing advanced nanoparticle solutions for the delivery and
expression of mRNA therapeutics, today announced preclinical proof
of concept for the combination of the two companies’ key
technologies.
The preclinical data demonstrate that tumor neoantigens
identified by Evaxion’s AI platform, PIONEER, drive a strong immune
response and lead to complete inhibition of tumor growth in a
preclinical model when delivered using Pantherna’s proprietary
lipid nanoparticle mRNA platform (PTXΔLNP®, PTXmRNA®).
“We are extremely pleased with the preclinical data that clearly
demonstrate the potential for our combined technologies. The data
provide further evidence that immunogenic sequences identified by
Evaxion’s AI platforms are able to drive a relevant immune response
on multiple vaccine platforms, including mRNA. This opens up many
opportunities in our current and future immuno-oncology and
infectious disease programs,” says Birgitte Rønø, CSO at
Evaxion.
“We are encouraged by the data and see an enormous potential of
combining Evaxion’s AI-based antigen discovery engines with our
state-of-the-art mRNA-LNP platforms. The preclinical data
substantiate the relevance of enhancing the efficiency of mRNA
actions in the body and validates the ability of our platform to
induce an immune response,” says Klaus Giese, CEO at Pantherna.
In continuation of these positive findings, Evaxion and
Pantherna will further explore optimal LNP formulations to
effectively deliver mRNA and DNA-encoded antigens identified by
Evaxion’s AI platforms.
About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company
developing AI-powered immunotherapies. Evaxion’s proprietary and
scalable AI technologies decode the human immune system to discover
and develop novel immunotherapies for cancer, bacterial diseases,
and viral infections. Evaxion has a broad pipeline of novel product
candidates, including three personalized cancer immunotherapies. It
is located in Hørsholm, Denmark, with 70 employees and is listed on
the Nasdaq New York stock exchange. For more information, please
visit: www.evaxion-biotech.com.
About Pantherna
Pantherna Therapeutics is a privately held biopharmaceutical
company developing first-in-class mRNA therapeutics. Pantherna’s
innovative technology platform is based on advanced lipid
nanoparticles for the target-specific, selective delivery and
expression of therapeutic mRNA drugs in organs and tissues such as
the vascular endothelium.
Pantherna is based in Hennigsdorf, Brandenburg
(Innovationsforum) close to Berlin, Germany. For more information,
please visit https://pantherna-therapeutics.com/.
For more information, please contact:
Katrine Hertz MortensenVP, Communications and Public
Relationskhm@evaxion-biotech.com+45 3010 0203
Gerrit MaassCFOg.maass@pantherna-therapeutics.com+49 3302-202
240-0
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words “target,” “believe,”
“expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide COVID-19 pandemic and the ongoing conflict in
the region surrounding Ukraine and Russia; and
other uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please
refer to the risk factors included in our most recent Annual Report
on Form 20-F and other filings with the U.S. Securities
and Exchange Commission (SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024